Flow FL-100
Flow Neuroscience AB · Decision date Dec 8, 2025
What did the FDA approve?
FDA records P230024 as an original PMA application. The recorded decision is approval, dated Dec 8, 2025.
FDA approval order statement
FL-100 is intended for the treatment of moderate to severe major depressive disorder in the current episode, either as monotherapy or as an adjunctive treatment, in patients 18 years and older who are not considered treatment refractory to medication.
- Regulatory pathway
- Original PMA
- Clinical specialty
- Neurology
- Decision date
- Dec 8, 2025
Regulatory record facts
- Identifier
- P230024
- Regulatory pathway
- Premarket approval application
- Applicant
- Flow Neuroscience AB
- Product code
- JXK
- Decision code
- APPR
- Decision date
- Dec 8, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Cranial electrotherapy stimulator to treat depression.
- Applicant
- Flow Neuroscience AB
- Product code
- JXK
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P230024 received
Application receipt date recorded by FDA.
P230024 · FDA decision
APPR
P230024/S001 · Related supplement
Flow FL-100
Timeline entries are records held by MedtechLedger for P230024. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P230024
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Flow FL-100P230024/S001 | Flow Neuroscience AB | PMA supplement | Jul 14, 2026 | FDA |
Explore the linked device profile
Other records with product code JXK
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
ProlivRx SystemP250010 | Neurolief , Ltd. | PMA approval | Dec 31, 2025 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Flow Neuroscience AB
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 470 Ramona St., Palo Alto, CA, 94301
Sources and methodology
- Original FDA record: P230024
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 21, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records